Skip to main content
PMHS
OTC Life Sciences

Polomar Health Q2 Revenue Jumps to $1.5M, Turns Profitable, But Going Concern and Material Weaknesses Persist

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.14
Mkt Cap
$3.927M
52W Low
$0.065
52W High
$960,000
52W Position info
115% above low
Off High info
100% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

PMHS has more than doubled off its 52-week low of $0.065.

Summary

Polomar Health Services reported a dramatic revenue increase and a quarterly profit, but the company still faces substantial doubt about its ability to continue as a going concern and has material weaknesses in internal controls.


Key Events · Earnings and Guidance · PMHS

  • Revenue Surges to $1.5M

    Q2 2026 revenue was $1,528,705, up from $5,470 in Q2 2025. Six-month revenue reached $2,534,224, driven by prescription fulfillment for a single customer.

  • Company Turns Profitable

    Net income was $200,358 for Q2 2026 and $174,981 for the first half, compared to losses of $605,563 and $1,062,418 in the prior-year periods.

  • Going Concern Warning Repeats

    Management states substantial doubt exists about the company's ability to continue as a going concern, citing an accumulated deficit of $13,526,169 and dependence on raising capital.

  • Material Weaknesses in Controls

    The company disclosed material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient accounting expertise.


Analysis · PMHS · Life Sciences

Polomar Health Services reported Q2 2026 revenue of $1.53 million, up from just $5,470 a year earlier, and swung to a net profit of $200,358. The company's pharmacy business is scaling rapidly, but the filing also repeats a going concern warning and discloses material weaknesses in financial controls. The company remains highly dependent on a single customer and faces a $20 million lawsuit from a former partner.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PMHS was trading at $0.14 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.07 to $960,000.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PMHS - Latest Insights

PMHS
Nov 16, 2026, 3:26 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.12504
Real-time Price: $0.100 info
Change: -$0.02504 (-20%) info
Market Cap: $2.838M info
PMHS
Nov 13, 2026, 5:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.12504
Real-time Price: $0.100 info
Change: -$0.02504 (-20%) info
Market Cap: $2.838M info
PMHS
Nov 03, 2026, 4:41 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1875
Real-time Price: $0.100 info
Change: -$0.0875 (-47%) info
Market Cap: $2.838M info
PMHS
Oct 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.120
Real-time Price: $0.100 info
Change: -$0.020 (-17%) info
Market Cap: $2.838M info
PMHS
Jul 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.118
Real-time Price: $0.100 info
Change: -$0.018 (-15%) info
Market Cap: $2.838M info